SPSB1 inhibition induces cancer immune evasion by modulating the KLF6/PD-L1 axis in non-small cell lung cancer cells
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Chenglai Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Kruppel-Like Factor 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains among the most lethal malignancies, with aggressive progression and limited survival. The binding of programmed cell death 1 ligand 1 (PD-L1) to its receptor PD-1, which is expressed on T cells, functions as a critical checkpoint that undermines anti-tumor immune defenses. Despite encouraging anti-tumor efficacy, PD-1 inhibition yields only modest objective response rates in clinical practice. This limitation stems, in part, from an incomplete elucidation of the molecular circuitry controlling PD-L1 expression within the tumor microenvironment. In this work, we delineated a previously unrecognized regulatory axis that modulates sensitivity to PD-1 blockade in NSCLC, centering on SplA/ryanodine receptor domain and SOCS box containing 1 (SPSB1), a substrate-recognition subunit of a Cullin-RING E3 ubiquitin ligase. SPSB1 is markedly upregulated in NSCLC, and its genetic depletion suppressed NSCLC cell proliferation In vitro. Paradoxically, this deletion triggered PD-L1 upregulation, resulting in functional exhaustion of cocultured T cells In vitro, attenuated anti-tumor immunity in vivo, and diminished therapeutic efficacy in immunocompetent murine models. Notably, combined PD-1 mAb and SPSB1 knockdown markedly attenuated tumor growth in immunocompetent mouse models. Mechanistically, SPSB1 ubiquitinated Krüppel-like factor 6 (KLF6), destabilizing the transcription factor, thereby relieving KLF6-mediated promotion of PD-L1 transcription. Upstream, polypyrimidine tract binding protein 3 (PTBP3) bound SPSB1 3'UTR, stabilizing its mRNA. Rescue experiments confirmed that the KLF6/PD-L1 axis is necessary to transmit the signal triggered by SPSB1 loss. In conclusion, this work establishes that SPSB1 suppression combined with PD-1 blockade may be a potential combinatorial strategy for NSCLC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China.
- Department of Nursing, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China.
- Department of Oncology, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China. Electronic address: 1fy2016132@xxmu.edu.cn.
Förderung
- Natural Science Foundation of Henan Province
Zitieren
APA
Dong, C., Zhu, D., Zhang, J., Li, B., Zhao, J., Gan, S., & Shen, W. (2026). SPSB1 inhibition induces cancer immune evasion by modulating the KLF6/PD-L1 axis in non-small cell lung cancer cells. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118017
Vancouver
Dong C, Zhu D, Zhang J, Li B, Zhao J, Gan S, et al. SPSB1 inhibition induces cancer immune evasion by modulating the KLF6/PD-L1 axis in non-small cell lung cancer cells. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118017
BibTeX
@article{Dong2026,
author = {Dong, Chenglai and Zhu, Deqi and Zhang, Jincao and Li, Bin and Zhao, Jia and Gan, Shaoyin and Shen, Wei},
title = {SPSB1 inhibition induces cancer immune evasion by modulating the KLF6/PD-L1 axis in non-small cell lung cancer cells},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118017}
}
EUVIMED